
T cell and immune cell engagement is gaining traction, but what makes it different from other therapies? Patrick Baeuerle, Ph.D., chief scientific advisor at Cullinan Therapeutics, and Jeffrey Miller, M.D., deputy director of Masonic Cancer Center, join The Chain to discuss the advantages, similarities, and differences of T cell and immune cell engagers, and how they compare to other modalities such as CAR T cells. Hosted by Laszlo Radvanyi, Ph.D., their conversation covers engineering recogn...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Episode: 89 - James E. Crowe, Jr. on AHEAD 100, a New Strategy for Preparing for the Next Pandemic

Episode: 88 - Janice Reichert on the Evolution of Antibody Therapeutics

Episode: 87 - Jack Elands on How Novel ADC Payloads Could Improve Cancer Care GUEST: Jack Elands, Ph.D., Founder and CEO, Adcytherix

Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D
Free AI-powered recaps of The Chain: Protein Engineering Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.